NASDAQ:OACC

Oaktree Acquisition Corp. III Life Sciences Q3 2026 Earnings Results & Report

Oaktree Acquisition Corp. III Life Sciences logo
$10.73 +0.03 (+0.29%)
As of 04:00 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Oaktree Acquisition Corp. III Life Sciences reported Q3 2026 earnings on November 13, 2026. The company reported EPS of -$0.02.

Earnings Announcement Details

Quarter
Q3 2026
Time
After Market Closes

Oaktree Acquisition Corp. III Life Sciences EPS Results

Actual EPS
-$0.02
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Oaktree Acquisition Corp. III Life Sciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Oaktree Acquisition Corp. III Life Sciences Q3 2026 Earnings FAQ

Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC) reported earnings of -$0.02 per share for Q3 2026. The report was announced on Friday, November 13, 2026.

Oaktree Acquisition Corp. III Life Sciences Earnings Headlines

No headlines for this company have been tracked by MarketBeat.com
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Oaktree Acquisition Corp. III Life Sciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Oaktree Acquisition Corp. III Life Sciences and other key companies, straight to your email.

About Oaktree Acquisition Corp. III Life Sciences

Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC) is a special purpose acquisition company (SPAC) formed to pursue a business combination with a company in the life sciences sector. Its potential transactions could include a merger, acquisition, or similar combination.

The company was sponsored by Oaktree Capital Management. As a SPAC, it did not have its own operating business or sell products and services; its intended role was to identify and combine with a business in its target sector.

View Oaktree Acquisition Corp. III Life Sciences Profile